MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Eli Lilly and Co.

Abrir

SetorSaúde

866.91 2.08

Visão Geral

Variação de preço das ações

24h

Atual

Mín

845.8

Máximo

871.37

Indicadores-chave

By Trading Economics

Rendimento

7.8B

8.8B

Vendas

2.1B

14B

P/E

Médio do Setor

70.036

57.333

EPS

5.32

Rendimento de Dividendos

0.71

Margem de lucro

65.172

Funcionários

47,000

EBITDA

1.2B

6.1B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+16.73% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.71%

2.63%

Próximos Ganhos

1 de mai. de 2025

Próxima data de ex-dividendo

14 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-50B

735B

Abertura anterior

864.83

Fecho anterior

866.91

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

Eli Lilly and Co. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de abr. de 2025, 09:26 UTC

Grandes Movimentos do Mercado

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

18 de abr. de 2025, 15:57 UTC

Grandes Movimentos do Mercado

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

17 de abr. de 2025, 11:52 UTC

Grandes Movimentos do Mercado

Eli Lilly Shares Jump Premarket After First Pill for Diabetes, Weight Loss Shows Positive Study Results

9 de abr. de 2025, 18:18 UTC

Grandes Movimentos do Mercado

Pharma Shares Reverse Losses After Tariff Pause

9 de abr. de 2025, 09:39 UTC

Grandes Movimentos do Mercado

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4 de abr. de 2025, 22:38 UTC

Ações em Alta

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 de abr. de 2025, 23:15 UTC

Grandes Movimentos do Mercado

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

22 de abr. de 2025, 09:31 UTC

Ações em Alta

Stocks to Watch Tuesday: Tesla, Novo Nordisk, Hertz -- WSJ

17 de abr. de 2025, 18:27 UTC

Principais Notícias

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- Update

17 de abr. de 2025, 10:45 UTC

Principais Notícias

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- WSJ

11 de abr. de 2025, 16:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Novo Remade Denmark. Then Came the Stock Selloff. -2-

11 de abr. de 2025, 16:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Novo Remade Denmark. Then Came the Stock Selloff. -- Barrons.com

11 de abr. de 2025, 09:30 UTC

Principais Notícias

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

11 de abr. de 2025, 05:00 UTC

Principais Notícias

Wall Street Pulls Back on the Weight-Loss Drug Hype -- Barrons.com

10 de abr. de 2025, 05:00 UTC

Ganhos

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. -- Barrons.com

8 de abr. de 2025, 21:26 UTC

Ganhos

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

2 de abr. de 2025, 16:53 UTC

Principais Notícias

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

1 de abr. de 2025, 22:31 UTC

Principais Notícias

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1 de abr. de 2025, 21:47 UTC

Principais Notícias

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

19 de mar. de 2025, 15:54 UTC

Principais Notícias

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

14 de mar. de 2025, 09:30 UTC

Principais Notícias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

28 de fev. de 2025, 12:00 UTC

Principais Notícias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 de fev. de 2025, 15:14 UTC

Principais Notícias

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

26 de fev. de 2025, 14:30 UTC

Principais Notícias

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

10 de fev. de 2025, 12:00 UTC

Principais Notícias

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7 de fev. de 2025, 10:30 UTC

Principais Notícias

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 de fev. de 2025, 16:16 UTC

Principais Notícias
Ganhos

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 de fev. de 2025, 14:56 UTC

Ganhos

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

6 de fev. de 2025, 14:32 UTC

Conversa de Mercado
Ganhos

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

6 de fev. de 2025, 13:18 UTC

Principais Notícias
Ganhos

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

Comparação entre Pares

Variação de preço

Eli Lilly and Co. Previsão

Preço-alvo

By TipRanks

16.73% parte superior

Previsão para 12 meses

Média 1,003.6 USD  16.73%

Máximo 1,124 USD

Mínimo 888 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Eli Lilly and Co. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

19 ratings

19

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

732.41 / N/ASuporte e Resistência

Curto Prazo

Very Strong Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.